STAT October 17, 2024
Peter J. Pitts

Differing philosophies within and outside of government could doom the hub

Over the summer, the Food and Drug Administration announced the creation of the Rare Disease Innovation Hub to serve as a point of collaboration and connectivity between the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER), patient organizations, and product innovators with the goal of ultimately improving outcomes for patients. But how can it become more than...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: FDA, Govt Agencies
Related Articles:
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments

Share This Article